Education
About Us
Working with TipRanks
Follow Us
Gilead Sciences (GILD)
:GILD
GILD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$78.36 - $121.83
Previous CloseN/A
Volume1.95M
Average Volume (3M)6.14M
Market Cap
$142.75B
Enterprise Value$157.48B
Total Cash (Recent Filing)$5.21B
Total Debt (Recent Filing)$24.95B
Price to Earnings (P/E)22.9
Beta0.41
Next Earnings
Oct 23, 2025EPS Estimate
2.16Next Dividend Ex-Date
Sep 15, 2025Dividend Yield2.71%
Share Statistics
EPS (TTM)2.01
Shares Outstanding1,240,806,900
10 Day Avg. Volume4,862,568
30 Day Avg. Volume6,138,451
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue5.46
Enterprise Value/Gross Profit6.95
Enterprise Value/Ebitda14.35
Forecast
1Y Price Target
$125.52Price Target Upside9.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering23
Bulls Say, Bears Say
Bulls Say
Market PerformanceInvestors reacted positively to the news about Yeztugo, sending the stock up by 8%.
Product AwarenessPhysician unaided brand awareness for Yeztugo is significantly higher than typical launches, at 72%.
Product LaunchYeztugo is off to a great start with the first prescription within hours of approval and product shipped within 24 hours.
Bears Say
Future Growth ConcernsGilead shares have reached an all-time high, making it questionable whether there are sufficient drivers in other franchises to support further expansion.
Market Access ChallengesThere are ongoing access headwinds for Yeztugo, with CVS Health not covering it on its commercial/ACA formularies.
Regulatory UncertaintyThe timing of Health and Human Services action to mandate unrestricted access to Yeztugo remains uncertain.
Gilead Sciences News
GILD FAQ
What was Gilead Sciences’s price range in the past 12 months?
Gilead Sciences lowest stock price was $78.36 and its highest was $121.83 in the past 12 months.
What is Gilead Sciences’s market cap?
Gilead Sciences’s market cap is $142.75B.
When is Gilead Sciences’s upcoming earnings report date?
Gilead Sciences’s upcoming earnings report date is Oct 23, 2025 which is in 45 days.
How were Gilead Sciences’s earnings last quarter?
Gilead Sciences released its earnings results on Aug 07, 2025. The company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.05.
Is Gilead Sciences overvalued?
According to Wall Street analysts Gilead Sciences’s price is currently Undervalued.
Does Gilead Sciences pay dividends?
Gilead Sciences pays a Quarterly dividend of $0.79 which represents an annual dividend yield of 2.71%. See more information on Gilead Sciences dividends here
What is Gilead Sciences’s EPS estimate?
Gilead Sciences’s EPS estimate is 2.16.
How many shares outstanding does Gilead Sciences have?
Gilead Sciences has 1,240,806,900 shares outstanding.
What happened to Gilead Sciences’s price movement after its last earnings report?
Gilead Sciences reported an EPS of $2.01 in its last earnings report, beating expectations of $1.96. Following the earnings report the stock price went up 8.279%.
Which hedge fund is a major shareholder of Gilead Sciences?
Currently, no hedge funds are holding shares in GILD
Gilead Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$125.52 (9.10% Upside)
$125.52 (9.10% Upside)
Blogger Sentiment
Bullish
GILD Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 2.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 3.4%
Last 30 Days ▲ 3.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
50.77%
12-Months-Change
Fundamentals
Return on Equity
33.26%
Trailing 12-Months
Asset Growth
4.00%
Trailing 12-Months
Company Description
Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
GILD Company Deck
GILD Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for Gilead with significant achievements, including the FDA approval of Yeztugo and strong sales growth in the HIV segment. However, there are challenges with declining Veklury sales and competition in cell therapy, along with potential policy impacts. Overall, the highlights significantly outweigh the lowlights, indicating a strong position for Gilead moving forward.View all GILD earnings summariesGILD Revenue Breakdown
68.21% HIV
11.44% Oncology
10.51% Liver Disease
6.26% Veklury
3.59% Other
GILD Stock 12 Month Forecast
Average Price Target
$125.52
▲(9.10% Upside)
Technical Analysis
Ownership Overview
0.09% Insiders
30.24% Mutual Funds
18.56% Other Institutional Investors
22.98% Public Companies and Individual Investors